Savara Inc. (SVRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Savara Inc. (SVRA) closed at USD 4.74 on 2026-10-15, a change of +9.2 % over the past year, with a market capitalization of USD 914.3M.

Savara Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Savara Inc. key figures

Previous close

USD 4.74 (2026-10-15)

1-year change

+9.2 %

Market cap

USD 914.3M

Enterprise value

USD 986.51M

P/E ratio (trailing)

-7.67

P/E ratio (forward)

-12.13

EPS (trailing)

-0.58

EPS (forward)

-0.37

PEG ratio

n/a

Price to book

7.88

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

22.78

Employees

70

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Savara Inc. and compare it with other stocks.